ArticleAnnals of surgical oncology2026
Disparities in Surgical Care of Patients with Colorectal Cancer Liver Metastases.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundUp to 25% of patients with colorectal cancer present with liver metastases (CRLM), and 50% develop metastases over time. Surgical and ablative management of CRLM can be curative, but certain demographic and socioeconomic factors disproportionately hinder vulnerable patient populations from receiving advanced local therapies.
methodsWe queried the 2011-2021 National Cancer Database for cases of CRLM. We explored patient and facility characteristics associated with receipt of local intervention versus no intervention for metastatic liver lesions.
resultsOf 72,273 cases, 18.0% underwent hepatectomy or ablation. Controlling for patient- and center-level factors, non-Hispanic Black and Hispanic/Latino patients were less likely to undergo liver intervention than were non-Hispanic white patients (odds ratio [OR] 0.83 [95% confidence interval (CI) 0.78-0.88] vs. OR 0.92 [95% CI 0.85-0.99]). Patients treated at academic programs had significantly higher odds of liver intervention than did those in community cancer programs (OR 2.24 [95% CI 2.06-2.43]). Patients with private, Medicaid, Medicare, or other government insurance had higher odds of liver intervention than did uninsured patients (OR 2.07 [95% CI 1.86-2.30], OR 1.40 [95% CI 1.24-1.58], OR 1.81 [95% CI 1.61-2.03], OR 2.20 [95% CI 1.81-2.66], respectively). Patients in the highest income quartile were more likely to have liver intervention than those in the lowest quartile (OR 1.18 [95% CI 1.10-1.27]). Patients receiving liver intervention traveled farther than those receiving non-surgical care (p<0.001).
conclusionSurgical or local ablative management of CRLM is necessary to achieve cure for appropriately selected patients. However, this advanced liver interventional care is not equally distributed among patient populations. Significant socioeconomic and demographic disparities exist in the receipt of local liver interventional management among patients with CRLM and require further exploration to improve resource allocation.
Indexed as
Identifiers
41832361What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.